Table 1 Participant demographics, comorbidities and laboratory values
Omega 3 (n = 19) | Control (n = 21) | Total (n = 40) | |
|---|---|---|---|
Male | 14 (73.7%) | 20 (95.2%) | 34 (85.0%) |
NZ European | 13 (68.4%) | 18 (85.7%) | 31 (77.5%) |
Age years) | 63.3 (12.3) | 59.3 (14.7) | 61.2 (13.6) |
Weight kg | 89.0 (22.3) | 91.4 (19.2) | 88.8 (20.6) |
BMI kg/m2 | 30.3 (6.5) | 29.7 (5.2) | 30.0 (5.8) |
Hypertension | 7 (36.8%) | 9 (42.9%) | 16 (40%) |
Hyperlipidaemia | 5 (26.3%) | 5 (23.8%) | 10 (25%) |
Type 2 diabetes | 3 (15.8%) | 1 (4.8%) | 5 (10%) |
Ischaemic heart disease | 0 (0) | 2 (9.5%) | 2 (5%) |
Serum urate mmol/l | 0.44 (0.08) | 0.46 (0.08) | 0.45 (0.08) |
eGFR (ml/min/1.73m2) | 68.5 (15.6) | 69.7 (18.9) | 69.1 (17.2) |
Cholesterol (mmol/l) | 5.4 (1.0) | 5.2 (1.1) | 5.3 (1.0) |
Triglycerides (mmol/l) | 2.1 (0.8) | 2.4 (1.3) | 2.3 (1.1) |
HDL (mmol/l) | 1.3 (0.3) | 1.2 (0.3) | 1.2 (0.3) |
LDL (mmol/l) | 3.1 (1.0) | 3.0 (0.9) | 3.0 (0.9) |
Cholesterol (total/LDL) | 4.3 (1.1) | 4.5 (1.4) | 4.4 (1.3) |
Total red cell omega 3% | 4.6 (1.2) | 4.4 (0.9) | 4.5 (1.0) |
20:5n-3 (EPA)% | 0.8 (0.3) | 0.8 (0.3) | 0.8 (0.3) |
22:6n-3 (DHA)% | 2.1 (0.5) | 1.9 (0.4) | 2.0 (0.5) |
HbA1C (mmol/mol) | 41.4 (16.2) | 35.8 (11.1) | 38.5 (13.9) |
On allopurinol | 8 (42.0%) | 9 (43.0%) | 17 (42.5%) |
Serum Oxypurinol (µmol/l) | 69.3 (38.4) (n = 8) | 42.8 (28.6) (n = 9) | 55.3 (35.2) |
Tophi present | 4 (21.1%) | 3 (14.3) | 7 (17.5%) |
Flare prophylaxis | 4 (21.1%) | 2 (9.5%) | 6 (15%) |